SIRT1, 2, and 3 inhibition assay

JT Jeffery M. Tharp
JH J. Trae Hampton
CR Catrina A. Reed
AE Andreas Ehnbom
PC Peng-Hsun Chase Chen
JM Jared S. Morse
YK Yadagirri Kurra
LP Lisa M. Pérez
SX Shiqing Xu
WL Wenshe Ray Liu
request Request a Protocol
ask Ask a question
Favorite

The continuous assay for comparing isoform specificity of S2P04 was performed using the universal fluorogenic sirtuin substrate described by Schuster et al.41. Briefly, the inhibition reactions were performed in 50-µL volumes at 37 °C in black, half-area, 96-well plates. The sirtuin enzyme (0.25 µM) was preincubated with different concentrations of the peptide S2P04 (0.0064–50 µM for SIRT1 and SIRT2, 0.5–100 µM for SIRT3) or TB (0.16–150 µM for SIRT1–SIRT3), and 1 mM NAD+ in assay buffer (20 mM Tris, pH 7.8, 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT) for 15 min. Following incubation, the reaction started with the addition of the fluorogenic substrate (5 µM), and product formation was monitored by measuring the fluorescence intensity every 20 s for 5 min (SIRT2) or 30 min (SIRT1 and SIRT3) in a BioTek Synergy H1 microplate reader at λex = 320 nm and λem = 408 nm (gain = 130 and read height = 7 mm). Initial rates of product formation were determined by a linear regression of the plot of fluorescence intensity vs. time and normalized relative to 0% (max inhibitor) and 100% (no inhibitor) controls. The assay was repeated to determine the IC50 values of all BuK peptides for SIRT2. IC50 values were determined by nonlinear regression of the plot of the normalized initial rate vs. inhibitor concentration using GraphPad Prism. The determined IC50 values are provided in Supplementary Table 2, and inhibition curves can be seen in Supplementary Fig. 20.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A